Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents

Annals of Surgical Oncology

Volumn 19, Issue SUPPL. 3, 2012, Pages

  Cohen, Stephanie M ^a   Mukerji, Ridhwi ^a   Samadi, Abbas K ^a   Zhao, Huiping ^b   Blagg, Brian S J ^b   Cohen, Mark S ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; HEAT SHOCK PROTEIN 90 INHIBITOR; KU 363; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; RAF PROTEIN; TANESPIMYCIN; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DOWN-REGULATION; FIBROBLASTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; LACTAMS, MACROCYCLIC; MICE; MOUTH NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF;

EID: 84865000590     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1971-1     Document Type: Article

References (27)

1. A Jemal R Siegel J Xu E Ward 2010 Cancer statistics, 2010 CA Cancer J Clin 60 277 300 20610543 10.3322/caac.20073
2. S Marur AA Forastiere 2008 Head and neck cancer: changing epidemiology, diagnosis, and treatment Mayo Clin Proc 83 489 501 18380996 10.4065/83.4.489
3. Kim L, King T, Agulnik M. Head and neck cancer: changing epidemiology and public health implications. Oncology (Williston Park). 2010;24:915-9.
4. CC Ragin F Modugno SM Gollin 2007 The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus J Dent Res 86 104 114 17251508 10.1177/154405910708600202 1:CAS:528:DC%2BD2sXitVCrurs%3D
5. JS Cooper TF Pajak AA Forastiere J Jacobs BH Campbell SB Saxman, et al. 2004 Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck N Engl J Med 350 1937 1944 15128893 10.1056/NEJMoa032646
6. PK Goon MA Stanley J Ebmeyer L Steinsträsser T Upile W Jerjes, et al. 2009 HPV & head and neck cancer: a descriptive update Head Neck Oncol 1 36 19828033 10.1186/1758-3284-1-36
7. RI Morimoto MP Kline DN Bimston JJ Cotto 1997 The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones Essays Biochem 32 17 29 9493008 1:CAS:528:DyaK1cXktVSrsQ%3D%3D
8. H Zhang F Burrows 2004 Targeting multiple signal transduction pathways through inhibition of Hsp90 J Mol Med 82 488 499 15168026 1:CAS:528: DC%2BD2cXmt1Kktrs%3D
9. MV Powers P Workman 2006 Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors Endocr Relat Cancer 13 S125 S135 17259553 10.1677/erc.1.01324 1:CAS:528:DC%2BD2sXivF2mtbk%3D
10. A Maloney P Workman 2002 HSP90 as a new therapeutic target for cancer therapy: the story unfolds Expert Opin Biol Ther 2 3 24 11772336 10.1517/14712598.2.1.3 1:CAS:528:DC%2BD38XnsVaksw%3D%3D
11. AS Sreedhar E Kalmar P Csermely YF Shen 2004 Hsp90 isoforms: functions, expression and clinical importance FEBS Lett 562 11 15 15069952 10.1016/S0014-5793(04)00229-7
12. GE Brandt BS Blagg 2009 Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases Curr Top Med Chem 9 1447 1461 19860731 10.2174/156802609789895683 1:CAS:528:DC%2BC3cXhsFakurk%3D
13. A Donnelly BS Blagg 2008 Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket Curr Med Chem 15 2702 2717 18991631 10.2174/092986708786242895 1:CAS:528:DC%2BD1cXhtlWiur3M
14. SC Bishop JA Burlison BS Blagg 2007 Hsp90: a novel target for the disruption of multiple signaling cascades Curr Cancer Drug Targets 7 369 388 17979631 10.2174/156800907780809778 1:CAS:528:DC%2BD2sXmsV2msrk%3D
15. P Workman 2004 Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone Cancer Lett 206 149 157 15013520 10.1016/j.canlet.2003.08.032 1:CAS:528:DC%2BD2cXhvFaiu7s%3D
16. X Yin H Zhang F Burrows L Zhang CG Shores 2005 Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo Clin Cancer Res 11 3889 3896 15897590 10.1158/1078-0432.CCR-04-2272 1:CAS:528:DC%2BD2MXktFyqsrc%3D
17. X Yin H Zhang K Lundgren L Wilson F Burrows CG Shores 2010 BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy Int J Cancer 126 1216 1225 19662650 1:CAS:528:DC%2BC3cXjsFCr
18. V Smith EA Sausville RF Camalier HH Fiebig AM Burger 2005 Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models Cancer Chemother Pharmacol 56 126 137 15841378 10.1007/s00280-004-0947-2 1:CAS:528:DC%2BD2MXksl2gsr8%3D
19. P Workman 2003 Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics Mol Cancer Ther 2 131 138 12589030 1:CAS:528: DC%2BD3sXht1Wktb0%3D
20. DB Solit I Osman D Polsky KS Panageas A Daud JS Goydos, et al. 2008 Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma Clin Cancer Res 14 8302 8307 19088048 10.1158/1078-0432.CCR-08-1002 1:CAS:528:DC%2BD1cXhsV2it7nP
21. Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, et al. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs. [Epub ahead of print].
22. T Zhang Y Li Y Yu P Zou Y Jiang D Sun 2009 Characterization of celastrol to inhibit hsp90 and cdc37 interaction J Biol Chem 284 35381 35389 19858214 10.1074/jbc.M109.051532 1:CAS:528:DC%2BD1MXhsFCqurjN
23. H Kimura H Yukitake Y Tajima H Suzuki T Chikatsu S Morimoto, et al. 2010 ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation Chem Biol 17 18 27 20142037 10.1016/j.chembiol.2009.12.012 1:CAS:528:DC%2BC3cXht12nsrY%3D
24. MG Marcu TW Schulte L Neckers 2000 Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins J Natl Cancer Inst 92 242 248 10655441 10.1093/jnci/92.3.242 1:CAS:528:DC%2BD3cXhtFShsbk%3D
25. VS Nirmalanandhan A Duren P Hendricks G Vielhauer GS Sittampalam 2010 Activity of anticancer agents in a three-dimensional cell culture model Assay Drug Dev Technol 8 581 590 20662735 10.1089/adt.2010.0276 1:CAS:528: DC%2BC3cXhtlensLbO
26. SN Shelton ME Shawgo SB Matthews Y Lu AC Donnelly K Szabla, et al. 2009 KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells Mol Pharmacol 76 1314 1322 19741006 10.1124/mol.109.058545 1:CAS:528: DC%2BD1MXhsFajtbzK
27. B Tillotson K Slocum J Coco N Whitebread B Thomas KA West, et al. 2010 Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo J Biol Chem 285 39835 39843 20940293 10.1074/jbc.M110.141580 1:CAS:528:DC%2BC3cXhsFChtL7P